Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC PINK:PEMTF) (the “Company”) is pleased to announce its financial results for the first quarter ending March 31, 2020. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. The press release is intended to be read in conjunction with the Company’s unaudited Condensed Interim Consolidated Financial Statements and Management Discussion & Analysis for the three months ended March 31, 2020, which are filed under the Company’s profile on SEDAR (, and also available on the Company’s website.

First Quarter 2020 Key Highlights include:

  • The Company acquired online cannabidiol (CBD) product distributor Nature’s Exclusive from Unified Funding, LLC.
  • Agreement finalized with Sativida OU (Estonia) and Sativida OU’s subsidiary, VIDA BCN LABS S.L (collectively, “Sativida”) to acquire Sativida in stages.
  • The Company acquired the intellectual property and trade names of Sativida in Spain, which will be licensed back in exchange for a royalty associated with gross revenues generated by Sativida.
  • The Company entered into a Licensing and Royalty Agreement with Phenome One Corporation (“Phenome”) for the right to cultivate, harvest, process and sell a selection of cultivars from Phenome’s genetic library, and the Company was granted unlimited access to a Phenome’s proprietary nutrient intellectual property (IP) and catalogue.
  • The Company entered into a Joint Venture with BevCanna Enterprises Inc (“BevCanna”) to distribute BevCanna branded beverage products infused with hemp-derived CBD in the European market.
  • Consolidated Q1 2020 gross revenue was $7.65 million, with cost of goods sold of $7.05 million, resulting in gross profits of $605,150. Operating and other operating expenses for the three months ended March 31, 2020 were $5.24 million.
  • The Company raised $1.72 million through share subscriptions received for the issuance of units at $0.28 and received $309,000 in proceeds from the exercise of warrants.
  • The Company ended Q1 2020 with $2.1 million in cash.

Management Commentary

In the midst of evolving challenges resulting from the global novel coronavirus outbreak, the Company realigned priorities to include focus on the health and safety of our employees, customers and suppliers. The way our team adapted and performed was exceptional. I am also pleased to announce that, despite the unprecedented uncertainties resulting from the coronavirus, our operations and supply chains performed without interruption, and the Company achieved targets in line with expectations. In order to capitalize on the global market, we recognize the need to be flexible and proactive in addressing market trends. For the second quarter our objectives are to yield increased revenues and higher gross margins. Due to the initial cost of customer acquisition, transitioning more customers into our monthly subscription will significantly increase margins.” stated Ryan Hoggan CEO of the Company.

About Mota Ventures Corp.

Mota Ventures is an established natural health products and eCommerce technology company focusing on the CBD and psychedelic medicine sectors. The company has a strong presence in both North America and Europe. In the United States, Mota Ventures offers a CBD hemp-oil product line derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, the company’s Verrian operations is currently conducting clinical studies utilizing proprietary products for the treatment of opiate addiction. The highly skilled Verrian team also manages Mota Ventures‘ 110,000 square foot manufacturing facility in Radebeul, Germany. In addition, Mota Ventures‘ Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. The company is also seeking to acquire additional revenue-producing natural health product brands and operations in both Europe and North America with the goal of establishing an international distribution network utilizing its eCommerce technology platform.



Ryan Hoggan

Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at or

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this press release, which has been prepared by management.

Cautionary Note Regarding Forward-Looking Statement

All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to the Company’s goals of yielding increased revenues and higher gross margins, capitalizing on the global market, and its plans to acquire revenue-producing CBD brands and operations in Europe and North America. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.

SOURCE: Mota Ventures Corp.

View source version on

July 8, 2020 – 12:05 AM PDT
News by QuoteMedia

 BioHarvest Sciences Inc. (CSE: BHSC) (the “Company” or “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, January 21st, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time). Ilan Sobel, CEO of BHSC, will host the event and discuss progress on Bioharvest’s Growth Plan, which will include highlights of the 2020 milestones achieved, key business capabilities built, and will provide an important overview of 2021 Priorities.

The presentation will be approximately 35 minutes, followed by a live question and answer session.

Keep reading... Show less

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”), reports that it has sold its 50% interest in Cobra Ventures Inc. (“Cobra”), which sale included all funds previously advanced by World Class to Cobra, to the remaining shareholder of Cobra, for $2,500,000 in cash

An investment group led by Richard Goldstein retains 100% control of Cobra, and its senior secured debenture of Hydrx Farms Ltd. (“Hydrx”), acquired by Cobra in October 2020.

Keep reading... Show less

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”), an innovative global cannabinoid company, today announced that Kurt Schmidt, President and Chief Executive Officer, will speak at the 24th Annual CIBC Western Institutional Investor Conference on Friday, January 22, 2021 at 4:10 p.m. EST.

A recording will be available on the Investors section of the Company’s website at .

Keep reading... Show less
  • Disease control of root-rot Aphanomyces zoospores in laboratory tests.
  • Outstanding Efficacy: 100% control at economic application rates within 24 hours.
  • Aphanomyces is a soil-borne root-rot disease that destroys peas, lentils, and legume crops.

MustGrow Biologics Corp. (CSE: MGRO) (OTC: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce successful laboratory test results of its patented mustard-derived biopesticide on Aphanomyces euteiches zoospores (“Aphanomyces”) via an independent third party facility: 100% control at economic application rates within 24 hours. MustGrow will now advance to larger scale greenhouse and field tests. Study results and applicability are patent-protected under MustGrow’s existing suite of issued patents.

MustGrow’s remarkably safe and effective organic biopesticide is plant-based – harnessing the mustard seed’s natural defense mechanism to control diseases, pests, and weeds with an organic food-grade biopesticide.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or “the Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced the hiring of CPG industry veteran Ty Gent as the Company’s new Chief Operating Officer (“COO”). As COO, Gent will be responsible for operational consistency and efficiency across markets and implementation of structural enhancements to facilitate scaling.

This press release features multimedia. View the full release here:

Keep reading... Show less